Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis

(Wyss Institute for Biologically Inspired Engineering at Harvard) The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have access to commercially develop their therapeutic, biomaterial-based, cancer vaccine technology that promotes anti-cancer immunity.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news